PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE VACCINE W/ ADJUVANTS:INFANT RHESUS

细菌肺炎链球菌是导致耳炎的主要原因 感染、鼻窦感染和儿童脑膜炎。 恒河 猴子也容易感染链球菌 肺炎杆菌 肺炎链球菌的免疫应答 猴子体内的疫苗与人类相似。 几种可能的疫苗 保护人类免受肺炎链球菌感染， 开发了 这个项目的目的是研究 三种不同的佐剂与一种研究性的 预防七种肺炎球菌肺炎球菌疫苗 肺炎球菌在恒河猴幼猴鼻内定植 类型14. 16只幼年恒河猴（4组，每组4只）， 在2、4和6个月大时用七种成分免疫 肺炎球菌疫苗;一组（对照组）未接受 疫苗，其他三组接受疫苗与明矾， 明矾加MPL或明矾加QS-21。 血液是在那个时候采集的 接种第三剂疫苗后1个月。 对七种肺炎球菌的免疫反应 包括在疫苗中。 疫苗具有免疫原性; 明矾单独给最低的响应，明矾加MPL给最高 血清型6 B、9V和14的应答，以及明矾加QS-21， 血清型4、18 C、19 F和23 F的最高应答。 九个月大的时候 年龄的动物用增加量的 肺炎链球菌14型。 对照组的所有4只动物 组被少量的肺炎链球菌定殖。 12只接种疫苗的动物中只有4只成为殖民地 肺炎球菌的挑战。 这项研究表明，MPL QS-21佐剂在诱导免疫方面上级单独的明矾 对肺炎疫苗的反应。 肺炎球菌疫苗减少 幼年猴的鼻咽定植。 基于 从这项研究的积极结果，在人类的临床试验应该是 考虑MPL和QS-21佐剂。

The bacteria Streptococcus pneumoniae is the leading cause of ear infections, sinus infections, and meningitis in children. Rhesus monkeys are also susceptible to infection with Streptococcus pneumoniae bacteria. The immune response to Streptococcus pneumoniae vaccines in monkeys is similar to humans. Several potential vaccines to protect humans against Streptococcus pneumoniae infections have been developed. The purpose of this project was to study the ability of three different adjuvants combined with an investigational pneumococcal vaccine against seven types of pneumococcus to protect infant rhesus monkeys from colonization of the nose with pneumococcus type 14. Sixteen infant rhesus monkeys (four groups of four) were immunized at 2, 4, and 6 months of age with a seven component pneumococcal vaccine; one group (control group) did not receive vaccine, the other three groups received vaccine with either alum, alum plus MPL, or alum plus QS-21. Blood was obtained at the time vaccine was administered and 1 month after the third dose of vaccine. The immune response to each of the seven types of pneumococcus included in the vaccine was evaluated. The vaccine was immunogenic; alum alone gave the lowest response, alum plus MPL gave the highest response for serotypes 6B, 9V, and 14, and alum plus QS-21 gave the highest response for serotypes 4, 18C, 19F, and 23F. At nine months of age the animals were challenged with increasing amounts of Streptococcus pneumoniae type 14. All four animals in the control group were colonized with low amounts of Streptococcus pneumoniae. Only four of twelve animals who were vaccinated became colonized following pneumococcal challenge. This study demonstrates that MPL and QS-21 adjuvants are superior to alum alone in inducing an immune response to pneumococcal vaccine. Pneumococcal vaccine decreased nasopharyngeal colonization in the juvenile monkeys. Based on the positive results from this study, clinical trials in humans should be considered with both MPL and QS-21 adjuvants.